These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 37204852)

  • 1. Medullary Thyroid Cancer: Updates and Challenges.
    Gild ML; Clifton-Bligh RJ; Wirth LJ; Robinson BG
    Endocr Rev; 2023 Sep; 44(5):934-946. PubMed ID: 37204852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives.
    Zhang Y; Zheng WH; Zhou SH; Gu JL; Yu Q; Zhu YZ; Yan YJ; Zhu Z; Shang JB
    Cell Commun Signal; 2024 Sep; 22(1):460. PubMed ID: 39342195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve
    Wirth LJ; Brose MS; Elisei R; Capdevila J; Hoff AO; Hu MI; Tahara M; Robinson B; Gao M; Xia M; Maeda P; Sherman E
    Future Oncol; 2022 Sep; 18(28):3143-3150. PubMed ID: 35969032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Contemporary Review of the Treatment of Medullary Thyroid Carcinoma in the Era of New Drug Therapies.
    Seib CD; Beck TC; Kebebew E
    Surg Oncol Clin N Am; 2023 Apr; 32(2):233-250. PubMed ID: 36925182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Precision medicine in endocrinology exemplified by medullary thyroid cancer].
    Brandenburg T; Machlah YM; Führer D
    Inn Med (Heidelb); 2024 Mar; 65(3):202-210. PubMed ID: 38231404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medullary Thyroid Cancer - Feature Review and Update on Systemic Treatment.
    Dabelić N; Jukić T; Fröbe A
    Acta Clin Croat; 2020 Jun; 59(Suppl 1):50-59. PubMed ID: 34219884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic treatment and management approaches for medullary thyroid cancer.
    Ernani V; Kumar M; Chen AY; Owonikoko TK
    Cancer Treat Rev; 2016 Nov; 50():89-98. PubMed ID: 27664392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma.
    Elisei R; Bottici V; Cappagli V; Ramone T; Tacito A; Ciampi R; Romei C
    Ann Endocrinol (Paris); 2019 Jun; 80(3):187-190. PubMed ID: 31053251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fundamentals and recent advances in the evaluation and management of medullary thyroid carcinoma.
    Gigliotti BJ; Brooks JA; Wirth LJ
    Mol Cell Endocrinol; 2024 Oct; 592():112295. PubMed ID: 38871174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomics and Epigenomics of Medullary Thyroid Carcinoma: From Sporadic Disease to Familial Manifestations.
    Barletta JA; Nosé V; Sadow PM
    Endocr Pathol; 2021 Mar; 32(1):35-43. PubMed ID: 33492588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on C-Cell Neuroendocrine Neoplasm: Prognostic and Predictive Histopathologic and Molecular Features of Medullary Thyroid Carcinoma.
    Jung CK; Agarwal S; Hang JF; Lim DJ; Bychkov A; Mete O
    Endocr Pathol; 2023 Mar; 34(1):1-22. PubMed ID: 36890425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. State of the art and future directions in the systemic treatment of medullary thyroid cancer.
    Jager EC; Broekman KE; Kruijff S; Links TP
    Curr Opin Oncol; 2022 Jan; 34(1):1-8. PubMed ID: 34669647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.
    Subbiah V; Hu MI; Mansfield AS; Taylor MH; Schuler M; Zhu VW; Hadoux J; Curigliano G; Wirth L; Gainor JF; Alonso G; Adkins D; Godbert Y; Ahn MJ; Cassier PA; Cho BC; Lin CC; Zalutskaya A; Barata T; Trask P; Scalori A; Bordogna W; Heinzmann S; Brose MS
    Thyroid; 2024 Jan; 34(1):26-40. PubMed ID: 38009200
    [No Abstract]   [Full Text] [Related]  

  • 14.
    Qi XP; Jin BY; Li PF; Wang S; Zhao YH; Cao ZL; Yu XH; Cheng J; Fang XD; Zhao JQ
    Thyroid; 2019 Oct; 29(10):1447-1456. PubMed ID: 31364476
    [No Abstract]   [Full Text] [Related]  

  • 15. Germline RET mutation carriers in Japanese patients with apparently sporadic medullary thyroid carcinoma: A single institution experience.
    Kihara M; Miyauchi A; Yoshioka K; Oda H; Nakayama A; Sasai H; Yabuta T; Masuoka H; Higashiyama T; Fukushima M; Ito Y; Kobayashi K; Miya A
    Auris Nasus Larynx; 2016 Oct; 43(5):551-5. PubMed ID: 26837867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Advanced Medullary Thyroid Carcinoma: Current Systemic Therapy Options.
    Jara MA
    Crit Rev Oncog; 2024; 29(3):83-90. PubMed ID: 38683155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Evolving Treatment Landscape of Medullary Thyroid Cancer.
    Laganà M; Cremaschi V; Alberti A; Vodopivec Kuri DM; Cosentini D; Berruti A
    Curr Treat Options Oncol; 2023 Dec; 24(12):1815-1832. PubMed ID: 37979019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma.
    Grubbs EG; Williams MD; Scheet P; Vattathil S; Perrier ND; Lee JE; Gagel RF; Hai T; Feng L; Cabanillas ME; Cote GJ
    Thyroid; 2016 Nov; 26(11):1553-1562. PubMed ID: 27610696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current understanding and management of medullary thyroid cancer.
    Roy M; Chen H; Sippel RS
    Oncologist; 2013; 18(10):1093-100. PubMed ID: 24037980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medullary thyroid carcinoma in children: current state of the art and future perspectives.
    Kiriakopoulos A; Dimopoulou A; Nastos C; Dimopoulou D; Dimopoulou K; Menenakos E; Zavras N
    J Pediatr Endocrinol Metab; 2022 Jan; 35(1):1-10. PubMed ID: 34592078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.